Xenetic Biosciences, Inc. — Q2 2019 Form 10-Q
Reporting period: Three and six months ended June 30, 2019. The company is a clinical-stage biopharmaceutical developer focused on oncology candidates and biologic-drug platforms. It reported no revenue for the periods presented.
Financial performance and position
| Metric | Q2 2019 / June 30, 2019 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None reported | None reported in Q2 2018 or first half 2018 |
| Research and development expense | $0.49 million for Q2; $0.95 million for H1 | $0.93 million for Q2 2018; $1.63 million for H1 2018 |
| General and administrative expense | $0.89 million for Q2; $1.75 million for H1 | $1.07 million for Q2 2018; $2.19 million for H1 2018 |
| Net loss | $1.38 million for Q2; $2.70 million for H1 | $2.03 million for Q2 2018; $3.85 million for H1 2018 |
| Net loss applicable to common stockholders | $6.58 million for H1, including a $3.88 million deemed dividend | $3.85 million for H1 2018 |
| Basic and diluted loss per share | $(1.56) for Q2; $(7.79) for H1 | $(2.78) for Q2 2018; $(5.29) for H1 2018 |
| Operating cash flow | $(2.31) million for H1 | $(3.75) million for H1 2018 |
| Cash and restricted cash | $1.03 million | $0.64 million at December 31, 2018 |
| Working capital | Approximately $71,000 | Deficit of approximately $0.4 million at December 31, 2018 |
| Total assets / liabilities / equity | $15.63 million / $5.24 million / $10.39 million | At June 30, 2019 |
There are no meaningful revenue or gross-margin measures because the company reported no revenue. No material borrowings are identified in the provided filing text; liabilities primarily comprise accounts payable, accrued items, and deferred taxes.
Changes versus comparable periods
- Q2 net loss narrowed 32% year over year, while H1 net loss narrowed 30%. Lower R&D spending, mainly reduced XBIO-101 trial activity, and lower G&A contributed to the improvement.
- Despite lower H1 net loss, loss applicable to common stockholders and per-share loss increased, principally because the March offering triggered a $3.88 million deemed dividend under the Series B preferred-stock down-round provision.
- H1 operating cash use fell to $2.31 million from $3.75 million. March 2019 equity and warrant financing provided $2.70 million net proceeds.
- The company effected a 1-for-12 reverse stock split on June 25, 2019. Common shares outstanding were 922,227 at June 30; the filing reported 3,743,889 as of August 9, reflecting subsequent issuances.
Business developments, outlook, and risks
- The XCART CAR T platform acquisition closed July 19, 2019, after quarter-end. The company issued approximately 406,250 shares to the sellers and approximately 218,750 shares to OPKO and the Scripps Research Institute in connection with the related assignments. It expects to focus on developing XCART for B-cell lymphomas. The transaction is expected to be accounted for as an asset acquisition.
- On July 19, the company completed a public offering generating approximately $15.0 million gross and $13.4 million net proceeds. It said proceeds would support research, development, clinical programs—including XCART—and general corporate purposes. The offering also included purchase warrants, creating potential future dilution.
- Management said the company has incurred substantial losses, expects continued near-term operating losses, and faces conditions raising substantial doubt about its ability to continue as a going concern. Management believes the March and July financings and existing resources are adequate for operations, but anticipates possible longer-term additional capital needs. No formal revenue, earnings, or cash-flow guidance is provided.
- XBIO-101 enrollment closed in March 2019 following slower-than-expected enrollment and retention; further development was suspended. The company’s other collaboration programs had generated no commercial products or revenue through June 30.
- Key risks include financing needs, clinical and commercialization uncertainty, XCART integration and development, dependence on collaborations and licensing, competition, and potential dilution. The July offering restored compliance with Nasdaq’s publicly held-share requirement after the reverse split had caused a shortfall.
- The filing reports no material legal proceedings and no material changes to previously disclosed risk factors. Management stated disclosure controls were effective at a reasonable-assurance level and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- How quickly the post-quarter $13.4 million net proceeds are used and whether further financing will be required.
- XCART acquisition accounting, development milestones, regulatory plans, and any additional obligations, including the approximately $230,000 loan repayment referenced in the filing.
- Potential dilution from the July offering warrants and Series B preferred-stock conversion terms, including applicable issuance limits.
- Whether XBIO-101 remains suspended and what evidence or funding would be required to resume development.
- Cash runway and progress on any collaborations or licensing that could generate revenue; the filing notes that more than 90% of historical milestone and sublicense revenue came from one collaborator.